Table 2_Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.docx by Bin Liao (714989)

“…Simultaneous knockout of HIF1α and HIF2α in GBM cells resulted in the highest LDH release and apoptosis rates under hypoxic conditions, accompanied by the most significant decrease in IGF1R, p-PDK1, and p-AKT levels. …”

Table 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.docx by Bo Peng (273834)

“…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…”

Table 4_Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.docx by Bin Liao (714989)

“…Simultaneous knockout of HIF1α and HIF2α in GBM cells resulted in the highest LDH release and apoptosis rates under hypoxic conditions, accompanied by the most significant decrease in IGF1R, p-PDK1, and p-AKT levels. …”

Supplementary file 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.doc... by Bo Peng (273834)

“…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…”

Table 3_Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.docx by Bin Liao (714989)

“…Simultaneous knockout of HIF1α and HIF2α in GBM cells resulted in the highest LDH release and apoptosis rates under hypoxic conditions, accompanied by the most significant decrease in IGF1R, p-PDK1, and p-AKT levels. …”

Presentation 1_Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022–2041.pptx by Bo Peng (273834)

“…Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022–2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable.…”

Table 6_Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.docx by Bin Liao (714989)

“…Simultaneous knockout of HIF1α and HIF2α in GBM cells resulted in the highest LDH release and apoptosis rates under hypoxic conditions, accompanied by the most significant decrease in IGF1R, p-PDK1, and p-AKT levels. …”

Data Sheet 1_Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.docx by Yeon-Woo Kang (18285202)

“…Crucially, TLP led to a shift in the composition of tumor-infiltrating lymphocytes, with a decrease in PD-1⁺ tumor-reactive CD8 T cells and an increase in PD-1⁻ bystander cells. …”

Bias risk assessment of included studies. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for hs-CRP. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for IL-6. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Antibodies used for flow cytometry. by Shanhe Liu (5251313)

“…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Primer pairs used for qPCR. by Shanhe Liu (5251313)

“…</p><p>Results</p><p>Flow cytometry analysis revealed a significantly higher apoptosis rate in AN-LSCs compared to LSCs (p < 0.0001). …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”